ReviewFrontiers in oncology2025
Liquid biopsy in biliary tract cancers: early diagnosis, precision therapy, and prognostic evaluation.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- [Liquid Biopsy Revolutionizes the Precise Management of Tumors Across the Entire Course: Current Situation and Future Prospects].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2026Pooled it
- Extracellular vesicle biomarkers in pancreatic ductal adenocarcinoma: from bulk detection to single-extracellular vesicle profiling and endoscopic liquid biopsy.Journal of gastroenterology · 2026Review
- Mortality Trends of Biliary Tract Cancers in the United States, 1999-2023: a CDC-WONDER Analysis.Journal of gastrointestinal cancer · 2026Article
- Advancements and Clinical Applications Prospects of Epigenetic Biomarkers in Liquid Biopsy for Oral Squamous Cell Carcinoma.Current issues in molecular biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biliary tract cancers represent a heterogeneous group of malignancies, including gallbladder cancer, intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma, and distal cholangiocarcinoma. These cancers share several common characteristics, such as challenges in early diagnosis, aggressive biological behavior, limited treatment options, and a propensity for drug resistance, all of which contribute to a notably poor prognosis for patients. Therefore, discovering new tumor biomarkers is urgently needed for early diagnosis, personalized treatment, and the prediction and monitoring of treatment effectiveness. Given that biopsy procedures are invasive and that repeated biopsies can diminish patient compliance, the ongoing advancement of liquid biopsy technology-characterized by its non-invasiveness and accessibility-promises to usher in a new epoch in clinical oncology. Currently, liquid biopsy mainly focuses on detecting and analyzing circulating tumor cells, cell-free DNA, and extracellular vesicles. This review aims to summarize the latest research advancements and future clinical applications of liquid biopsy in the context of biliary tract cancers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.